SUOX is a promising diagnostic and prognostic biomarker for hepatocellular carcinoma

Journal of Hepatology

Volumn 59, Issue 3, 2013, Pages 510-517

  Jin, Guang Zhi ^a   Yu, Wen Long ^a   Dong, Hui ^a   Zhou, Wei Ping ^a   Gu, Yi Jin ^a   Yu, Hao ^a   Yu, Hua ^a   Lu, Xin Yuan ^a   Xian, Zhi Hong ^a   Liu, Yin Kun ^b   Cong, Wen Ming ^a   Wu, Meng Chao ^a  

^a SECOND MILITARY MEDICAL UNIVERSITY   (China)

^b FUDAN UNIVERSITY   (China)

Author keywords

Aldo keto reductase family 1 member B10; CD34; Diagnosis; High grade dysplastic nodules; Prognosis; Sulfite oxidase; Well differentiated small hepatocellular carcinoma

Indexed keywords

ALDO KETOREDUCTASE FAMILY 1 MEMBER B10; ALPHA FETOPROTEIN; CD34 ANTIGEN; OXIDOREDUCTASE; SULFITE OXIDASE; UNCLASSIFIED DRUG;

ARTICLE; CANCER GROWTH; CANCER PROGNOSIS; CANCER RECURRENCE; DIAGNOSTIC VALUE; DIFFERENTIAL DIAGNOSIS; DISEASE MARKER; HUMAN; HUMAN TISSUE; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION;

AFP; AKR1B10; ALDO-KETO REDUCTASE FAMILY 1 MEMBER B10; ALDO-KETOREDUCTASE FAMILY 1 MEMBER B10; CD34; DIAGNOSIS; DN; DYSPLASTIC NODULES; HBV; HCC; HEPATITIS B VIRUS; HEPATOCELLULAR CARCINOMA; HGDN; HIGH GRADE DYSPLASTIC NODULES; HIGH-GRADE DYSPLASTIC NODULES; MD-SHCC; MODERATELY DIFFERENTIATED HCC; OS; OVERALL SURVIVAL; PROGNOSIS; RECEIVER OPERATING CHARACTERISTIC; ROC; SULFITE OXIDASE; SUOX; TIME TO RECURRENCE; TTR; WD-SHCC; WELL-DIFFERENTIATED SMALL HEPATOCELLULAR CARCINOMA; Α-FETOPROTEIN;

ALDEHYDE REDUCTASE; ALPHA-FETOPROTEINS; ANTIGENS, CD34; CARCINOMA, HEPATOCELLULAR; COHORT STUDIES; DIAGNOSIS, DIFFERENTIAL; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; LIVER; LIVER NEOPLASMS; LOGISTIC MODELS; MALE; MIDDLE AGED; OXIDOREDUCTASES ACTING ON SULFUR GROUP DONORS; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 84882814626     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jhep.2013.04.028     Document Type: Article

References (29)

1. D.M. Parkin, F. Bray, J. Ferlay, and P. Pisani Global cancer statistics, 2002 CA Cancer J Clin 55 2005 74 108
2. L. Libbrecht, V. Desmet, and T. Roskams Preneoplastic lesions in human hepatocarcinogenesis Liver Int 25 2005 16 27
3. S.M. Hussain, P.E. Zondervan, J.N. IJzermans, S.W. Schalm, R.A. de Man, and G.P. Krestin Benign versus malignant hepatic nodules: MR imaging findings with pathologic correlation Radiographics 22 2002 1023 1036
4. T. Aihara, S. Noguchi, Y. Sasaki, H. Nakano, M. Monden, and S. Imaoka Clonal analysis of precancerous lesion of hepatocellular carcinoma Gastroenterology 111 1996 455 461
5. S.S. Thorgeirsson, and J.W. Grisham Molecular pathogenesis of human hepatocellular carcinoma Nat Genet 31 2002 339 346
6. V. de Ledinghen, D. Laharie, R. Lecesne, B. Le Bail, M. Winnock, and P.H. Bernard Detection of nodules in liver cirrhosis: spiral computed tomography or magnetic resonance imaging? A prospective study of 88 nodules in 34 patients Eur J Gastroenterol Hepatol 14 2002 159 165
7. G. Krinsky Imaging of dysplastic nodules and small hepatocellular carcinomas: experience with explanted livers Intervirology 47 2004 191 198
8. M. Roncalli, E. Roz, G. Coggi, M.G. Di Rocco, P. Bossi, and E. Minola The vascular profile of regenerative and dysplastic nodules of the cirrhotic liver: implications for diagnosis and classification Hepatology 30 1999 1174 1178
9. P. Tatrai, A. Somoracz, E. Batmunkh, P. Schirmacher, A. Kiss, and Z. Schaff Agrin and CD34 immunohistochemistry for the discrimination of benign versus malignant hepatocellular lesions Am J Surg Pathol 33 2009 874 885
10. G.Z. Jin, Y. Li, W.M. Cong, H. Yu, H. Dong, and H. Shu ITRAQ-2DLC-ESI-MS/MS based identification of a new set of immunohistochemical biomarkers for classification of dysplastic nodules and small hepatocellular carcinoma J Proteome Res 10 2011 3418 3428
11. R. Satow, M. Shitashige, Y. Kanai, F. Takeshita, H. Ojima, and T. Jigami Combined functional genome survey of therapeutic targets for hepatocellular carcinoma Clin Cancer Res 16 2010 2518 2528
12. L.M. McShane, D.G. Altman, W. Sauerbrei, S.E. Taube, M. Gion, and G.M. Clark Reporting recommendations for tumor marker prognostic studies (REMARK) J Natl Cancer Inst 97 2005 1180 1184
13. Pathologic diagnosis of early hepatocellular carcinoma A report of the international consensus group for hepatocellular neoplasia Hepatology 49 2009 658 664
14. F.T. Bosman, F. Carneiro, and R.H. Hruban WHO classification of tumours of the digestive system 4th ed. 2010 IARC Press Lyon pp. 205-216
15. L.H. Sobin, and C. Wittekind TNM classification of malignant tumors 6th ed. 2002 Wiley-Liss New York 81 83
16. W. Cong, L. Tan, S. Zhang, Z. Xian, W. Wu, and J. Pan Immunohistochemical spectrum in the detection and differentiation of intrahepatic neoplasms Zhonghua Zhong Liu Za Zhi 24 2002 553 556
17. W.M. Coston, S. Loera, S.K. Lau, S. Ishizawa, Z. Jiang, and C.L. Wu Distinction of hepatocellular carcinoma from benign hepatic mimickers using Glypican-3 and CD34 immunohistochemistry Am J Surg Pathol 32 2008 433 444
18. L. Bolondi, S. Gaiani, N. Celli, R. Golfieri, W.F. Grigioni, and S. Leoni Characterization of small nodules in cirrhosis by assessment of vascularity: the problem of hypovascular hepatocellular carcinoma Hepatology 42 2005 27 34
19. M. Kojiro Focus on dysplastic nodules and early hepatocellular carcinoma: an Eastern point of view Liver Transpl 10 2004 S3 S8
20. L. Di Tommaso, A. Destro, J.Y. Seok, E. Balladore, L. Terracciano, and A. Sangiovanni The application of markers (HSP70 GPC3 and GS) in liver biopsies is useful for detection of hepatocellular carcinoma J Hepatol 50 2009 746 754
21. L. Di Tommaso, G. Franchi, Y.N. Park, B. Fiamengo, A. Destro, and E. Morenghi Diagnostic value of HSP70, glypican 3, and glutamine synthetase in hepatocellular nodules in cirrhosis Hepatology 45 2007 725 734
22. M.Y. Cai, Z.T. Tong, F. Zheng, Y.J. Liao, Y. Wang, and H.L. Rao EZH2 protein: a promising immunomarker for the detection of hepatocellular carcinomas in liver needle biopsies Gut 60 2011 967 976
23. C. Kisker, H. Schindelin, A. Pacheco, W.A. Wehbi, R.M. Garrett, and K.V. Rajagopalan Molecular basis of sulfite oxidase deficiency from the structure of sulfite oxidase Cell 91 1997 973 983
24. M.C. Edwards, J.L. Johnson, B. Marriage, T.N. Graf, K.E. Coyne, and K.V. Rajagopalan Isolated sulfite oxidase deficiency: review of two cases in one family Ophthalmology 106 1999 1957 1961
25. J.L. Johnson, K.E. Coyne, R.M. Garrett, M.T. Zabot, C. Dorche, and C. Kisker Isolated sulfite oxidase deficiency: identification of 12 novel SUOX mutations in 10 patients Hum Mutat 20 2002 74
26. J. Jin, P.A. Krishack, and D. Cao Role of aldo-keto reductases in development of prostate and breast cancer Front Biosci 11 2006 2767 2773
27. S. Fukumoto, N. Yamauchi, H. Moriguchi, Y. Hippo, A. Watanabe, and J. Shibahara Overexpression of the aldo-keto reductase family protein AKR1B10 is highly correlated with smokers' non-small cell lung carcinomas Clin Cancer Res 11 2005 1776 1785
28. S. Heringlake, M. Hofdmann, A. Fiebeler, M.P. Manns, W. Schmiegel, and A. Tannapfel Identification and expression analysis of the aldo-ketoreductase1-B10 gene in primary malignant liver tumours J Hepatol 52 2010 220 227
29. L.Q. Wu, Y. Lu, H.J. Lu, and Z.H. Lv Can E-cadherin and CD34 be used as indicators of prognosis for hepatocellular carcinoma patients? Clin Chem Lab Med 46 2008 1122 1126